Daconib 45 mg (Dacomitinib): Uses, Dosage, Side Effects & Lung Cancer Treatment
Daconib 45 mg (Dacomitinib): Uses, Dosage, Side Effects & EGFR-Positive Lung Cancer Treatment
What Is Daconib 45 mg?
Daconib 45 mg contains dacomitinib, a targeted anticancer medicine designed to interfere with signalling pathways that help certain lung cancer cells grow and survive.
Dacomitinib is particularly relevant to non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) gene.
EGFR is a protein found on the surface of cells. Under normal circumstances, EGFR participates in signals involved in cell growth and division. Some cancers contain activating EGFR mutations that can cause excessive signalling, allowing tumour cells to continue growing and multiplying.
Dacomitinib belongs to the tyrosine kinase inhibitor (TKI) family. It works by blocking EGFR and related members of the ErbB receptor family, thereby interfering with abnormal growth signalling.
The medicine is used as a targeted treatment rather than conventional cytotoxic chemotherapy. Before treatment, appropriate molecular testing is required to establish whether the tumour has an eligible EGFR mutation.
The product information supplied for this page is:
- Product: Daconib 45 mg
- Generic: Dacomitinib
- Strength: 45 mg
- Dosage form: Tablets
- Pack: 30 tablets
Dacomitinib treatment should be initiated and supervised by a healthcare professional experienced in cancer treatment.
What Is Dacomitinib Used For?
Dacomitinib is used for selected adults with locally advanced or metastatic non-small-cell lung cancer whose tumours have activating EGFR mutations.
Patient-Friendly Explanation
Dacomitinib may be considered when lung cancer has specific EGFR changes that cause abnormal growth signals.
Instead of attacking rapidly dividing cells throughout the body in the same way as traditional chemotherapy, dacomitinib targets an important signalling pathway involved in certain EGFR-mutated lung cancers.
Medical Indication
The EMA describes dacomitinib as monotherapy for first-line treatment of adults with locally advanced or metastatic NSCLC containing activating EGFR mutations.
The FDA's approved indication specifically identifies metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitutions.
How Does Dacomitinib Work?
Dacomitinib works by inhibiting receptor tyrosine kinase signalling.
EGFR is part of the ErbB receptor family, which participates in cellular communication. When an activating EGFR mutation is present, signalling can remain excessively active.
A simplified pathway is:
EGFR activating mutation → abnormal receptor signalling → increased tumour-cell growth and survival
Dacomitinib interferes with this process:
Dacomitinib → EGFR/ErbB kinase inhibition → reduced growth signalling → inhibition of tumour-cell proliferation
Dacomitinib binds irreversibly to several members of the ErbB receptor family, including EGFR/HER1, HER2 and HER4. This distinguishes it from some EGFR inhibitors that act more selectively.
By suppressing abnormal receptor signalling, dacomitinib can reduce pathways involved in tumour-cell proliferation and survival.
Because the treatment depends on tumour biology, molecular testing is an important part of selecting appropriate patients. The presence of an eligible activating EGFR mutation should be confirmed before treatment.
Key Indications
Dacomitinib may be prescribed for:
- Locally advanced NSCLC
- Metastatic NSCLC
- EGFR-mutated NSCLC
- NSCLC with activating EGFR mutations
- Selected patients requiring first-line targeted treatment
The exact eligibility criteria depend on the regulatory indication applicable in the patient's country.
Daconib 45 mg Dosage & Administration
The standard recommended dose is 45 mg once daily, taken at approximately the same time each day. Treatment generally continues while the patient continues to benefit and adverse effects remain manageable.
Administration
- Take one 45 mg dose once daily as prescribed.
- Try to take it at approximately the same time each day.
- Swallow the tablet according to the product instructions.
- Follow the treatment schedule provided by the oncologist.
- Do not change the dose without medical advice.
Dose reduction or treatment interruption may be necessary if clinically significant adverse reactions develop.
Missed Dose
If a dose is missed, patients should follow the instructions provided by their oncologist or the applicable product information.
Do not take extra doses to compensate for a missed dose unless specifically instructed by a healthcare professional.
Common Side Effects
Dacomitinib is associated with several predictable adverse reactions.
Commonly reported effects include:
- Diarrhea
- Rash
- Stomatitis
- Nail disorders
- Dry skin
- Reduced appetite
- Conjunctivitis
- Weight loss
- Hair loss
- Itching
- Nausea
- Increased liver enzymes
These effects are documented in European regulatory information for dacomitinib.
Important Side Effects
Some adverse reactions require closer medical attention.
Diarrhea
Diarrhea is one of the most frequently reported adverse reactions. Persistent or severe diarrhea can cause dehydration and electrolyte disturbances.
Skin Reactions
Rash, dry skin, itching and other skin-related effects may occur.
Mouth Inflammation
Stomatitis can cause mouth soreness and difficulty eating or drinking.
Nail Changes
Dacomitinib can cause nail disorders and inflammation around the nails.
Liver Abnormalities
Liver enzyme elevations may occur, which is why laboratory monitoring can be necessary.
Interstitial Lung Disease
Interstitial lung disease is an important serious adverse reaction associated with dacomitinib.
When to Seek Medical Attention
Contact a healthcare professional promptly if you develop:
- Severe or persistent diarrhea
- New or worsening breathing difficulty
- Persistent cough
- Fever accompanied by breathing symptoms
- Severe skin reaction
- Extensive blistering or peeling
- Severe mouth inflammation
- Significant dehydration
- Unusual symptoms that rapidly worsen
Breathing symptoms are particularly important because serious interstitial lung disease can occur.
Drug Interactions
Dacomitinib can interact with other medicines, so the treating healthcare professional should be informed about all prescription medicines, over-the-counter products, vitamins and supplements.
Particular attention may be required with medicines that affect drug-metabolizing enzymes or gastrointestinal absorption.
Patients should not begin a new prescription, herbal product or supplement without checking with their healthcare professional.
Food & Administration Considerations
Follow the instructions supplied with the specific product.
Dacomitinib tablets should be taken consistently according to the prescribed schedule. Patients should discuss significant dietary changes or supplements with their healthcare team if there is concern about possible interactions.
Warnings & Precautions
Lung Considerations
Interstitial lung disease/pneumonitis is an important potential serious adverse reaction. New respiratory symptoms should be evaluated promptly.
Skin Health
Skin toxicity is common. Patients may require supportive skin care and, when necessary, treatment interruption or dose adjustment.
Gastrointestinal Effects
Diarrhea can become clinically significant. Early management is important to reduce dehydration risk.
Liver Monitoring
Elevated transaminases have been reported. Healthcare professionals may monitor liver function during treatment.
Eye Problems
Conjunctivitis and other ocular effects have been reported. New or worsening eye symptoms should be discussed with the treating team.
Pregnancy & Breastfeeding
Dacomitinib may cause fetal harm based on its pharmacological activity and nonclinical findings.
Patients who are pregnant, planning pregnancy or capable of becoming pregnant should discuss the risks and appropriate contraception with their healthcare professional before starting treatment.
Breastfeeding considerations should also be discussed with the treating physician because systemic anticancer therapy may pose risks to a breastfed infant.
Special Populations
Elderly Patients
Older adults may receive dacomitinib when clinically appropriate. Treatment decisions should consider overall health, concurrent medicines and tolerance of adverse effects.
Pediatric Patients
Dacomitinib is not routinely indicated for pediatric patients under the established adult NSCLC indication.
Renal Impairment
Patients with kidney impairment should inform their oncologist before treatment. Individual clinical circumstances may influence monitoring and treatment decisions.
Hepatic Impairment
Liver function should be considered before and during therapy, particularly because liver enzyme elevations can occur with dacomitinib.
Storage Instructions
Store Daconib according to the storage conditions stated on the product packaging.
General precautions:
- Keep the medicine in its original packaging.
- Keep it away from children.
- Protect it from inappropriate heat and moisture.
- Do not use tablets after their expiry date.
- Do not use damaged or visibly compromised tablets.
Always follow the manufacturer's specific storage instructions where they differ.
Frequently Asked Questions
1. What is Daconib 45 mg used for?
Daconib 45 mg contains dacomitinib and is used for selected adults with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer.
2. What is Dacomitinib?
Dacomitinib is an oral tyrosine kinase inhibitor used as targeted therapy for certain EGFR-mutated NSCLC.
3. Is Dacomitinib chemotherapy?
Dacomitinib is a targeted tyrosine kinase inhibitor rather than conventional cytotoxic chemotherapy.
4. How does Dacomitinib work?
It blocks EGFR and other ErbB-family receptor signalling involved in tumour-cell growth and survival.
5. What is the usual Dacomitinib dose?
The standard recommended dose is 45 mg once daily for eligible adult patients.
6. Does Dacomitinib treat EGFR-positive lung cancer?
Yes. Dacomitinib is indicated for NSCLC with activating EGFR mutations under applicable regulatory indications.
7. Does Dacomitinib cure lung cancer?
Dacomitinib should not be described as a guaranteed cure. It is a targeted treatment intended to control eligible EGFR-mutated NSCLC.
8. What are common Dacomitinib side effects?
Diarrhea, rash, stomatitis, nail disorders, dry skin, reduced appetite, nausea and other reactions are commonly reported.
9. Can Dacomitinib cause diarrhea?
Yes. Diarrhea is one of the most common adverse reactions associated with dacomitinib.
10. Can Dacomitinib cause skin problems?
Yes. Rash, dry skin, itching and other skin reactions are common.
11. Can Dacomitinib affect the lungs?
Yes. Interstitial lung disease is a potentially serious adverse reaction. New breathing problems should be medically assessed promptly.
12. Is EGFR testing necessary before Dacomitinib?
Yes. Appropriate testing should confirm an eligible activating EGFR mutation before treatment.
13. Is Dacomitinib taken once or twice daily?
The standard regimen is once daily.
14. How long is Dacomitinib treatment continued?
Treatment may continue while the patient continues to benefit and adverse effects remain tolerable.
15. Is Daconib 45 mg a prescription medicine?
Dacomitinib is a prescription oncology medicine and should be used under specialist medical supervision.
Global Medicine Information & Support by RootAid Pharma
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides educational medicine information and international pharmaceutical support relating to prescription and specialty medicines.
Our information resources cover areas including:
- Oncology medicines
- Targeted cancer therapies
- Lung cancer treatment information
- EGFR-mutated cancer
- Specialty medicines
- Prescription support
- International medicine information
- Treatment-related educational resources
For targeted medicines such as dacomitinib, appropriate molecular testing and specialist oncology assessment are important before treatment.
RootAid Pharma does not claim to manufacture Daconib or dacomitinib. Availability, prescription requirements, import regulations and supply conditions can vary by country.
Medical Disclaimer
This article is provided for general educational and informational purposes only. It does not replace a physician's diagnosis, individualized treatment plan, official prescribing information or professional medical advice.
Dacomitinib is a prescription anticancer medicine intended for patients with appropriate clinical and molecular characteristics. Treatment selection, EGFR testing, dosing, monitoring, dose modification and treatment duration must be determined by a qualified oncology professional.
Approved indications and prescribing requirements may differ between countries. Patients should always follow the official medicine information applicable in their country and the instructions of their healthcare professional.
Do not start, stop or change Dacomitinib treatment without medical supervision.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.